Several reports suggest elevated expression of STC2 in human hepatocellular carcinoma, neuroblastoma, breast cancer, colorectal cancer, renal cell carcinoma, esophageal squamous cell cancer, and prostate cancer (41, 64–69). This evidence concerns the gene STC2 and neuroblastoma.